NephSpace Transistor (https://transistor.fm) https://feeds.transistor.fm/nephspace NephSpace makes new kidney research easy and fun to follow. Every week, a practicing nephrologist picks the most interesting new papers and news in nephrology, and two hosts talk them through: the story, the key numbers, why it matters, and an honest take on what the study does and doesn't prove. Weekly episodes (about 30 minutes) cover that week's picks from the kidney journals, the big general journals and the specialty news. Deep Dives (15 to 20 minutes) follow one question further: two treatments racing for the same goal, a trial worth arguing about, a case that a new paper answers. Made for nephrologists, nephrology fellows and kidney-care clinicians. Curious, evenhanded, never condescending. Physician-led, AI-assisted. Dr. Wael Hussein, an academic nephrologist in Memphis, chooses every paper, reviews and edits every script, and approves every episode. First drafts are written with AI from the full text of each paper, a separate AI check compares every number with the papers, and the hosts' voices are AI-generated. Authors' industry ties are named on air, and Dr. Hussein's own disclosures are in every episode's notes. Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. Papers are summarized in our own words, with links to the originals. nephspace.com · hello@nephspace.com © 2026 NephSpace 5acebfab-772f-5121-a9f0-a219c552a4c1 yes en-us Thu, 01 Oct 2026 20:33:19 -0500 Thu, 01 Oct 2026 20:34:25 -0500 https://nephspace.com https://img.transistorcdn.com/6-uvSjkfkTs9wvjAwaiu2QcBMCJZ6YbG2-9H3cERoTw/rs:fill:0:0:1/w:1400/h:1400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9kZDYw/YjRhODU0MTA5MDRj/Y2YwNTQ3OThmNzE5/YmI4ZC5qcGc.jpg NephSpace https://nephspace.com episodic Wael Hussein NephSpace makes new kidney research easy and fun to follow. Every week, a practicing nephrologist picks the most interesting new papers and news in nephrology, and two hosts talk them through: the story, the key numbers, why it matters, and an honest take on what the study does and doesn't prove. Weekly episodes (about 30 minutes) cover that week's picks from the kidney journals, the big general journals and the specialty news. Deep Dives (15 to 20 minutes) follow one question further: two treatments racing for the same goal, a trial worth arguing about, a case that a new paper answers. Made for nephrologists, nephrology fellows and kidney-care clinicians. Curious, evenhanded, never condescending. Physician-led, AI-assisted. Dr. Wael Hussein, an academic nephrologist in Memphis, chooses every paper, reviews and edits every script, and approves every episode. First drafts are written with AI from the full text of each paper, a separate AI check compares every number with the papers, and the hosts' voices are AI-generated. Authors' industry ties are named on air, and Dr. Hussein's own disclosures are in every episode's notes. Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. Papers are summarized in our own words, with links to the originals. nephspace.com · hello@nephspace.com NephSpace makes new kidney research easy and fun to follow. nephrology, kidney, dialysis, CKD, nephrology fellows, medical education, journal club Wael Hussein hello@nephspace.com No No Deep Dive · Two Roads: Hemodiafiltration or Medium Cutoff Dialyzers? 2 2 Deep Dive · Two Roads: Hemodiafiltration or Medium Cutoff Dialyzers? full eff32d72-31ef-4d79-9868-ed8232cf9b39 https://share.transistor.fm/s/5b3a2d4e Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff dialyzers drop into today's machines but have no survival evidence against standard dialysis. A detective story with a Fight Night verdict, including who makes, sells and funds each road.


The takeaway: Both roads clear more middle molecules, but only hemodiafiltration has shown that people live longer, and only in patients who can get the dose.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius makes and sells the 5008X hemodiafiltration machine discussed in this episode. The episode names the industry ties of the review authors and of everyone quoted.


Chapters

  • 00:00 Cold open and disclosure
  • 01:11 The mystery: what middle molecules are, and why clearing them might matter
  • 02:47 Road one, change the treatment: CONVINCE, its quality-of-life and cost papers, and the JASN review
  • 08:36 Road two, change the filter: Theranova, ELISIO-HX and the medium cutoff evidence
  • 11:47 The showdown: MOTheR, the head-to-head trial
  • 15:13 Follow the money: who makes, sells and funds each road
  • 16:49 Fight Night verdict and the Monday-morning change


Papers discussed


Company and provider statements cited (promotional sources, labeled as such on air)

Also cited by name: Baxter's August 2020 Theranova authorization announcement, Nipro's July and August 2026 ELISIO-HX releases, and Fresenius's 2025 and 2026 releases on the 5008X rollout.


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff dialyzers drop into today's machines but have no survival evidence against standard dialysis. A detective story with a Fight Night verdict, including who makes, sells and funds each road.


The takeaway: Both roads clear more middle molecules, but only hemodiafiltration has shown that people live longer, and only in patients who can get the dose.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius makes and sells the 5008X hemodiafiltration machine discussed in this episode. The episode names the industry ties of the review authors and of everyone quoted.


Chapters

  • 00:00 Cold open and disclosure
  • 01:11 The mystery: what middle molecules are, and why clearing them might matter
  • 02:47 Road one, change the treatment: CONVINCE, its quality-of-life and cost papers, and the JASN review
  • 08:36 Road two, change the filter: Theranova, ELISIO-HX and the medium cutoff evidence
  • 11:47 The showdown: MOTheR, the head-to-head trial
  • 15:13 Follow the money: who makes, sells and funds each road
  • 16:49 Fight Night verdict and the Monday-morning change


Papers discussed


Company and provider statements cited (promotional sources, labeled as such on air)

Also cited by name: Baxter's August 2020 Theranova authorization announcement, Nipro's July and August 2026 ELISIO-HX releases, and Fresenius's 2025 and 2026 releases on the 5008X rollout.


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> Thu, 01 Oct 2026 19:34:24 -0500 Wael Hussein Wael Hussein 1211 Two dialysis patients, same city, same week. One gets a new machine that filters and replaces more than 20 liters every session. The other gets the same old machine with a new filter. Both are told it's the future. Hemodiafiltration has a survival trial but needs new machines. Medium cutoff dialyzers drop into today's machines but have no survival evidence against standard dialysis. A detective story with a Fight Night verdict, including who makes, sells and funds each road.


The takeaway: Both roads clear more middle molecules, but only hemodiafiltration has shown that people live longer, and only in patients who can get the dose.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius makes and sells the 5008X hemodiafiltration machine discussed in this episode. The episode names the industry ties of the review authors and of everyone quoted.


Chapters

  • 00:00 Cold open and disclosure
  • 01:11 The mystery: what middle molecules are, and why clearing them might matter
  • 02:47 Road one, change the treatment: CONVINCE, its quality-of-life and cost papers, and the JASN review
  • 08:36 Road two, change the filter: Theranova, ELISIO-HX and the medium cutoff evidence
  • 11:47 The showdown: MOTheR, the head-to-head trial
  • 15:13 Follow the money: who makes, sells and funds each road
  • 16:49 Fight Night verdict and the Monday-morning change


Papers discussed


Company and provider statements cited (promotional sources, labeled as such on air)

Also cited by name: Baxter's August 2020 Theranova authorization announcement, Nipro's July and August 2026 ELISIO-HX releases, and Fresenius's 2025 and 2026 releases on the 5008X rollout.


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> nephrology, kidney, dialysis, CKD, nephrology fellows, medical education, journal club No Weekly · Oct 2: The Middle-Molecule Race, a Dipstick Adherence Check, and AI for Fellows 1 1 Weekly · Oct 2: The Middle-Molecule Race, a Dipstick Adherence Check, and AI for Fellows full 87e0fabe-b0b9-45ec-ba2e-c2272165d465 https://share.transistor.fm/s/4b28f8c3 Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers and a take.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius sells hemodiafiltration machines, which are discussed in this episode.


Chapters

  • 00:00 Cold open and running order
  • 01:10 Hemodiafiltration: a JASN review makes the case for high-volume HDF as the global default, and how to prescribe it
  • 05:06 Medium cutoff dialyzers: Nipro's ELISIO-HX is cleared in the US and DaVita is scaling it up. What the interview shows, and what it doesn't
  • 08:13 Obinutuzumab: FDA approval for preventing relapse in frequently relapsing or steroid-dependent childhood-onset nephrotic syndrome, from age 2 into adulthood
  • 11:08 Nephrology and CKM syndrome: an AJKD perspective on shifting the specialty from organ failure to prevention
  • 13:59 Atherosclerosis in CKD: a CJASN review of mechanisms, risk prediction and the treatment menu
  • 17:54 GLP-1 receptor agonists in CKD: a case-based CJASN "How I Treat" piece
  • 21:03 The dipstick adherence check: glucosuria on routine urinalysis as a marker that patients are taking their SGLT2 inhibitor
  • 24:31 AI in practice: where AI can take paperwork off the nephrologist's desk
  • 27:44 Fellows and AI: training for the AI era without "never-skilling"
  • 30:24 Close


Papers and news in this episode


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers and a take.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius sells hemodiafiltration machines, which are discussed in this episode.


Chapters

  • 00:00 Cold open and running order
  • 01:10 Hemodiafiltration: a JASN review makes the case for high-volume HDF as the global default, and how to prescribe it
  • 05:06 Medium cutoff dialyzers: Nipro's ELISIO-HX is cleared in the US and DaVita is scaling it up. What the interview shows, and what it doesn't
  • 08:13 Obinutuzumab: FDA approval for preventing relapse in frequently relapsing or steroid-dependent childhood-onset nephrotic syndrome, from age 2 into adulthood
  • 11:08 Nephrology and CKM syndrome: an AJKD perspective on shifting the specialty from organ failure to prevention
  • 13:59 Atherosclerosis in CKD: a CJASN review of mechanisms, risk prediction and the treatment menu
  • 17:54 GLP-1 receptor agonists in CKD: a case-based CJASN "How I Treat" piece
  • 21:03 The dipstick adherence check: glucosuria on routine urinalysis as a marker that patients are taking their SGLT2 inhibitor
  • 24:31 AI in practice: where AI can take paperwork off the nephrologist's desk
  • 27:44 Fellows and AI: training for the AI era without "never-skilling"
  • 30:24 Close


Papers and news in this episode


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> Thu, 01 Oct 2026 19:32:24 -0500 Wael Hussein Wael Hussein 1856 Two ways to clear more middle molecules arrive in US dialysis units at once. A urine dipstick can show whether patients are taking their SGLT2 inhibitor. Two papers disagree about who should let AI write the notes. Nine picks from the week of September 21, 2026, each with the story, the numbers and a take.


Disclosure: Dr. Hussein serves on the Fresenius Medical Care US Home Medical Advisory Board. Fresenius sells hemodiafiltration machines, which are discussed in this episode.


Chapters

  • 00:00 Cold open and running order
  • 01:10 Hemodiafiltration: a JASN review makes the case for high-volume HDF as the global default, and how to prescribe it
  • 05:06 Medium cutoff dialyzers: Nipro's ELISIO-HX is cleared in the US and DaVita is scaling it up. What the interview shows, and what it doesn't
  • 08:13 Obinutuzumab: FDA approval for preventing relapse in frequently relapsing or steroid-dependent childhood-onset nephrotic syndrome, from age 2 into adulthood
  • 11:08 Nephrology and CKM syndrome: an AJKD perspective on shifting the specialty from organ failure to prevention
  • 13:59 Atherosclerosis in CKD: a CJASN review of mechanisms, risk prediction and the treatment menu
  • 17:54 GLP-1 receptor agonists in CKD: a case-based CJASN "How I Treat" piece
  • 21:03 The dipstick adherence check: glucosuria on routine urinalysis as a marker that patients are taking their SGLT2 inhibitor
  • 24:31 AI in practice: where AI can take paperwork off the nephrologist's desk
  • 27:44 Fellows and AI: training for the AI era without "never-skilling"
  • 30:24 Close


Papers and news in this episode


Physician-led, AI-assisted. Dr. Wael Hussein chooses the papers, reviews and edits every script, and approves every episode. The first draft is written with AI (Claude, by Anthropic) from the full text of each paper; a separate AI check compares every number with the papers; the hosts are AI voices (ElevenLabs). Everything is summarized in our own words; read the original before changing practice.


Educational content for healthcare professionals, not medical advice. Views are the creator's own and not those of his employer. No sponsors.


nephspace.com · hello@nephspace.com

]]> nephrology, kidney, dialysis, CKD, nephrology fellows, medical education, journal club No